Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix |
Domain |
PF00059 Lectin C-type domain PF00084 Sushi repeat (SCR repeat) PF07686 Immunoglobulin V-set domain PF00193 Extracellular link domain |
Function |
This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region. |
Biological Process |
GO:0001501 skeletal system development GO:0006022 aminoglycan metabolic process GO:0006023 aminoglycan biosynthetic process GO:0006024 glycosaminoglycan biosynthetic process GO:0006026 aminoglycan catabolic process GO:0006027 glycosaminoglycan catabolic process GO:0006790 sulfur compound metabolic process GO:0018146 keratan sulfate biosynthetic process GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030203 glycosaminoglycan metabolic process GO:0042339 keratan sulfate metabolic process GO:0042340 keratan sulfate catabolic process GO:0043062 extracellular structure organization GO:0044272 sulfur compound biosynthetic process GO:0044273 sulfur compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901565 organonitrogen compound catabolic process GO:1903510 mucopolysaccharide metabolic process |
Molecular Function |
GO:0005201 extracellular matrix structural constituent GO:0005539 glycosaminoglycan binding GO:0005540 hyaluronic acid binding GO:0030246 carbohydrate binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005775 vacuolar lumen GO:0005796 Golgi lumen GO:0043202 lysosomal lumen |
KEGG | - |
Reactome |
R-HSA-3656244: Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) R-HSA-3656225: Defective CHST6 causes MCDC1 R-HSA-3656243: Defective ST3GAL3 causes MCT12 and EIEE15 R-HSA-1474228: Degradation of the extracellular matrix R-HSA-1643685: Disease R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism R-HSA-3781865: Diseases of glycosylation R-HSA-3000178: ECM proteoglycans R-HSA-1474244: Extracellular matrix organization R-HSA-1630316: Glycosaminoglycan metabolism R-HSA-2022854: Keratan sulfate biosynthesis R-HSA-2022857: Keratan sulfate degradation R-HSA-1638074: Keratan sulfate/keratin metabolism R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ACAN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ACAN in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ACAN in various data sets.
|
Points in the above scatter plot represent the mutation difference of ACAN in various data sets.
|
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ACAN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ACAN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ACAN. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ACAN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ACAN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ACAN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ACAN |
Name | aggrecan |
Aliases | CSPGCP; aggrecan proteoglycan; CSPG1; chondroitin sulfate proteoglycan 1; aggrecan 1; AGCAN; SEDK; cartilage ...... |
Chromosomal Location | 15q26.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ACAN collected from DrugBank database. |
Details on drugs targeting ACAN.
|